- 全部删除
 
您的购物车当前为空
4E2RCat 是一种 eIF4E-eIF4G 相互作用的抑制剂,IC50为13.5 μM。


为众多的药物研发团队赋能,
让新药发现更简单!
4E2RCat 是一种 eIF4E-eIF4G 相互作用的抑制剂,IC50为13.5 μM。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 1 mg | ¥ 527  | In stock | |
| 5 mg | ¥ 1,250  | In stock | |
| 10 mg | ¥ 1,870  | In stock | |
| 25 mg | ¥ 3,170  | In stock | |
| 50 mg | ¥ 4,470  | In stock | |
| 100 mg | ¥ 5,910  | In stock | |
| 200 mg | ¥ 7,970  | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,250  | In stock | 
4E2RCat 相关产品
| 产品描述 | 4E2RCat is an inhibitor of eIF4E-eIF4G interaction (IC50 = 13.5 μM) and is capable of blocking coronavirus replication as monitored by viral protein expression and the production of infectious virus.  | 
| 靶点活性 |  eIF4E-eIF4G:13.5 μM  | 
| 体外活性 | 4E2RCat prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation. It significantly decreases human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers. 4E2RCat inhibits cap-dependent translation in a dose-dependent manner. 4E2RCat inhibits cap-dependent FF translation but not EMCV IRES-driven Ren translation. 4E2RCat inhibits coronavirus replication in a dose- and time-dependent manner[1].  | 
| 体内活性 | 4E2RCat inhibits protein synthesis in vivo and it is not a consequence of increased cell death[1].  | 
| 分子量 | 455.93 | 
| 分子式 | C22H14ClNO4S2 | 
| CAS No. | 432499-63-3 | 
| Smiles | OC(=O)c1cc(ccc1Cl)-c1ccc(\C=C2/SC(=S)N(Cc3ccccc3)C2=O)o1 | 
| 密度 | 1.56 g/cm3 (Predicted) | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| 溶解度信息 | DMSO: 15.5 mg/mL (34.00 mM), Sonication and heating are recommended.   | |||||||||||||||||||||||||
溶液配制表  | ||||||||||||||||||||||||||
DMSO 
  | ||||||||||||||||||||||||||
评论内容